Cardiac amyloidosis

Ultromics Announces Partnership to Expedite Development of Echo AI Algorithm for Early Detection of Cardiac Amyloidosis

Retrieved on: 
Wednesday, January 10, 2024
Research, Heart, MD, Echocardiography, TAP, Partnership, Deep learning, Diagnosis, University, Personalized medicine, Facial muscles, Cardiac amyloidosis, Heart failure, History, Coronary artery disease, Intelligence, Algorithm, Pfizer, Disease, FDA, Protein, Physician, Amyloidosis, Blood, Medical device

Under the partnership with Pfizer, Ultromics will research and pursue FDA clearance for its EchoGo® Amyloidosis algorithm that already has Breakthrough Device Designation as a medical device for the detection of cardiac amyloidosis.

Key Points: 
  • Under the partnership with Pfizer, Ultromics will research and pursue FDA clearance for its EchoGo® Amyloidosis algorithm that already has Breakthrough Device Designation as a medical device for the detection of cardiac amyloidosis.
  • "AI can help detect cardiac amyloidosis early through routine ultrasound scans of the heart, which is vitally important because current treatments for cardiac amyloidosis work best when implemented early in the course of disease.
  • AI-augmented detection of cardiac amyloidosis may be especially useful in clinical facilities lacking the time and resources needed for comprehensive assessment," he added.
  • Cardiac amyloidosis is a heterogeneous disease that results from the accumulation of abnormal proteins within the heart, impairing its ability to pump blood.

Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)

Retrieved on: 
Tuesday, November 7, 2023
MCF, Quality of life (healthcare), HIV disease progression rates, CMP, ID, Amyloid cardiomyopathy, Echocardiography, MRI, MPH, Health, Troponin, Cardiology, Cardiac amyloidosis, GLS, Journal, BWH, University, Patient, N-terminal prohormone of brain natriuretic peptide, Amyloidosis, Heart, LV, Publication, JACC, PET, Quality of life, TBR, Editorial, PET/CT, CAA, Amyloid, Harvard Medical School, ATTR, Devouring Radiant Light, Literature, Alys, Diagnosis, ECV, SAN, Medical imaging, Hospital, AL amyloidosis, Medicine, Iodine, Brigham

124I-evuzamitide may be more sensitive than standard diagnostics, with cardiac uptake shown in ATTR patients who had negative 99mTc-PYP scans.

Key Points: 
  • 124I-evuzamitide may be more sensitive than standard diagnostics, with cardiac uptake shown in ATTR patients who had negative 99mTc-PYP scans.
  • The manuscripts from Brigham and Women’s Hospital (BWH) and from the University of Tennessee Graduate School of Medicine were published in the Journal of American College of Cardiology – Cardiovascular Imaging (JACC CV Imaging).
  • The manuscripts, entitled “Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir” and “Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): A Phase 1/2 Study,” have been published online.
  • These studies suggest that 124I-evuzamitide is a promising novel radiotracer to detect and quantify cardiac amyloid in multiple types of amyloidosis.

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology

Retrieved on: 
Monday, October 2, 2023
Columbia University, Columbia University Irving Medical Center, Male, ASNC, LV, LVH, N-terminal prohormone of brain natriuretic peptide, Cardiac amyloidosis, Serum, Secondary systemic amyloidosis, Echocardiography, IQR, Hypertrophic cardiomyopathy, ID, Assistant, SUV, ICC, ECV, CMP, ATTR, SAN, Map, Cardiology, Amyloidosis, Oregon Health and Science University Center for Women's Health, PET/CT, Genetic testing, Diagnosis, Liver, CMR, HCM, Society, Arnold, Disease, Medical imaging, Medical device, Hospital, Medicine, Patient, Heart

Attralus-Sponsored Test-Retest repeatability study demonstrates excellent repeatability and supports the potential use of AT-01 imaging to monitor disease progression in patients with cardiac amyloidosis.

Key Points: 
  • Attralus-Sponsored Test-Retest repeatability study demonstrates excellent repeatability and supports the potential use of AT-01 imaging to monitor disease progression in patients with cardiac amyloidosis.
  • AT-01 uptake in cardiac amyloidosis shows moderate and statistically significant correlations with traditional measures of cardiac structure and function.
  • These data were included in oral and poster presentations at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC) taking place September 29-October 1, 2023, in Toronto, Canada.
  • These findings support the potential use of this novel imaging agent to monitor disease progression in patients with cardiac amyloidosis.

Anumana Receives U.S. FDA 510(k) Clearance for ECG-AI Algorithm to Detect Low Ejection Fraction

Retrieved on: 
Monday, October 2, 2023
Biotechnology, Medical Devices, Health, Health Technology, Cardiology, EAGLE, Heart, Partnership, Mayo Clinic, Heart failure, Prevalence, Trial of the century, Cardiac amyloidosis, Deep learning, Food and Drug Administration, EF, ECG, Intelligence, Multimedia, Research, Category, American Medical Association, Hospital, Patient, Risk, Algorithm, Disease, Diagnosis, Mortality, LEF, FDA, Pulmonary hypertension, Food, Hyperkalemia, Medical device, Medical imaging

Anumana, Inc. , a leading AI-driven health technology and nference portfolio company working in collaboration with Mayo Clinic , today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for ECG-AI LEF, a breakthrough artificial intelligence (AI)-powered medical device to detect low ejection fraction (LEF) in patients at risk of heart failure.

Key Points: 
  • Anumana, Inc. , a leading AI-driven health technology and nference portfolio company working in collaboration with Mayo Clinic , today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for ECG-AI LEF, a breakthrough artificial intelligence (AI)-powered medical device to detect low ejection fraction (LEF) in patients at risk of heart failure.
  • View the full release here: https://www.businesswire.com/news/home/20231002851453/en/
    Screen shot of sample data from Anumana's ECG-AI LEF, a breakthrough artificial intelligence (AI)-powered medical device to detect low ejection fraction (LEF) in patients at risk of heart failure.
  • Anumana spearheaded the effort to bring reimbursement to ECG-AI, receiving approval for two Category III CPT® codes from the American Medical Association in 2022.
  • To learn more about ECG-AI LEF and schedule a demo, visit us at anumana.ai .

Viz.ai Signs License Agreement with UCSF to Commercialize Three Cardiac Artificial Intelligence Algorithms

Retrieved on: 
Friday, August 25, 2023
Software, Apps, Applications, Technology, Medical Devices, Hospitals, University, Artificial Intelligence, Health Technology, Education, Surgery, Cardiology, Nursing, Health, Heart, Cardiovascular disease, Cardiac amyloidosis, ECG, University of California, Technology management, UCSF, Algorithm, Knowledge, AI, Pulmonary hypertension, Automated ECG interpretation, Death, Supraventricular tachycardia, Disease, Medical device

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has signed an exclusive agreement with University of California, San Francisco (UCSF) to commercialize three AI algorithms for the automated detection of cardiovascular diseases.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has signed an exclusive agreement with University of California, San Francisco (UCSF) to commercialize three AI algorithms for the automated detection of cardiovascular diseases.
  • Developed at UCSF by leading researchers, these AI algorithms to detect cardiac amyloidosis, pulmonary hypertension, and supraventricular tachycardia are based on analysis of electrocardiograms (ECGs), the most widely used diagnostic test for characterization of cardiac structure and electrical activity of the heart.
  • “Collectively, cardiac amyloidosis, pulmonary hypertension, and supraventricular tachycardia affect up to 75 million people worldwide and are extremely difficult to detect or can take years to diagnose.
  • “We are proud to work with UCSF to develop more AI-powered tools that can advance cardiac care.”

Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm

Retrieved on: 
Wednesday, June 21, 2023
Health, FDA, Medical Devices, Technology, Health Technology, Artificial Intelligence, Cardiology, Medical device, Human, Mayo Clinic, De novo, Heart failure, Classification, Cardiac amyloidosis, Cohort (statistics), ECG, Software, Doctor of Philosophy, Publication, Patient, Algorithm, AI, Pulmonary hypertension, Automated ECG interpretation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breakthrough, Food, Hyperkalemia, Pfizer, Electrophysiology, Disease, Nature Medicine, Lancet

This breakthrough device designation was granted to provide patients and healthcare providers timely access to the algorithm, subject to approval.

Key Points: 
  • This breakthrough device designation was granted to provide patients and healthcare providers timely access to the algorithm, subject to approval.
  • Anumana previously announced a multi-year research agreement with Pfizer to develop ECG-AI solutions to aid in early identification of cardiac amyloidosis.
  • Anumana has received four Breakthrough Device Designations from the U.S. FDA for algorithms aimed at early identification of low ejection fraction, pulmonary hypertension, hyperkalemia, and now, cardiac amyloidosis.
  • “Receiving the FDA Breakthrough Device Designation for our Cardiac Amyloidosis ECG-AI Algorithm recognizes the significant potential of this tool to detect disease early.”

Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection

Retrieved on: 
Wednesday, April 26, 2023
Heart, Immunoglobulin light chain, Janssen Pharmaceuticals, Cardiac amyloidosis, Heart failure, Janssen, Marketing, Protein, ATTR, AL, Patient, Artificial intelligence, Diagnosis, Mortality, Johnson & Johnson, Transthoracic echocardiogram, FDA, Disease, Medical device, Medical imaging, Pharmaceutical industry, Amyloidosis

OXFORD, England, April 26, 2023 /PRNewswire/ -- Ultromics , a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis.

Key Points: 
  • OXFORD, England, April 26, 2023 /PRNewswire/ -- Ultromics , a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis.
  • "Receiving a breakthrough designation for EchoGo Amyloidosis, emphasises the importance of this innovation," said Dr Ross Upton, CEO and Founder of Ultromics.
  • Ultromics' Amyloidosis platform is the company's second technology to receive FDA Breakthrough Device Designation within the last year.
  • Its HFpEF device, EchoGo Heart Failure received Breakthrough Device Designation in 2022 and Marketing Authorization in 2023.

Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease

Retrieved on: 
Thursday, December 15, 2022
Software, Research, Data Management, Technology, Medical Devices, Hospitals, Artificial Intelligence, Health Technology, Science, Cardiology, FDA, Health, Other Science, Atrial fibrillation, Kidney disease, Diagnosis, Quality of life, Triage, Pulmonary hypertension, Mayo Clinic, Automated ECG interpretation, Cardiac amyloidosis, FDA, Pfizer, Classification, Degenerative disease, Heart, Algorithm, Human, Hyperkalemia, ECG, Research, De novo, Blood, Patient, Nature Medicine, Literature, Medical device, Lancet, Pramana

Anumana, Inc. , an AI-driven health technology company and portfolio company of nference , has entered into a multi-year agreement with Pfizer, Inc. for Anumana to develop an artificial intelligence electrocardiogram algorithm (AI-ECG) designed to enable the early suspicion of cardiac amyloidosis.

Key Points: 
  • Anumana, Inc. , an AI-driven health technology company and portfolio company of nference , has entered into a multi-year agreement with Pfizer, Inc. for Anumana to develop an artificial intelligence electrocardiogram algorithm (AI-ECG) designed to enable the early suspicion of cardiac amyloidosis.
  • The research agreement with Pfizer will help deepen Anumanas efforts to implement AI-enabled early detection software that can reveal signals from ECGs that humans cannot interpret.
  • Multiple Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical trial validation.
  • Anumana algorithms are investigational medical devices and have not yet received regulatory approval or clearance.

Global Genetic Testing Market Research Report 2022 Featuring Major Players - Abbott Laboratories, Myriad Genetics, F. Hoffmann-La Roche, Illumina, and Thermo Fisher Scientific - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 18, 2022
Health, Genetics, Lists of diseases, Adoption, Psoriasis, Globe, CDC, Statistics, News, Female, Disease, Risk, Government, Prevalence, Growth, Abbott Laboratories, DTC, Diagnosis, CAGR, Parkinson's disease, Research, Association for Molecular Pathology v. Myriad Genetics, Inc., Mortality, Brugada syndrome, Bipolar disorder, Cancer, Degenerative disease, Genetic disorder, Goal, Illumina, Inc., Health, Awareness, Conditional sentence, Breast, Incidence, Genetic testing, Cardiac amyloidosis, Infertility, Chromosome, Gene, AMD, Vaccine, Pharmaceutical industry, Medical device, Dietary supplement, Marketing

The "Global Genetic Testing Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genetic Testing Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global genetic testing market is growing at a significant CAGR during the forecast period.
  • The global genetic testing market is projected to considerably grow in the upcoming year due to the prevalence of genetic disorders, cancer, and chronic disease.
  • The report covers the analysis of various players operating in the global genetic testing market.

Attralus Announces Presentation of Clinical Data for AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent, at the 18th International Symposium on Amyloidosis

Retrieved on: 
Thursday, September 8, 2022
Whole body imaging, University, Columbia University, Spleen, Cardiac amyloidosis, College of Physicians and Surgeons, Physician, Liver, SAN, SPECT/CT, ATTR, ISA, N-terminal prohormone of brain natriuretic peptide, Kidney, Program, Heart, AL, Serum, Pathology, Diagnosis, Arnold, GLOBE, PAR, PET/CT, Iodine, Surgeon, International Symposium on Endovascular Therapy, Patient, Medical imaging, Amyloidosis, Cardiology, Medicine, MD

These data were included in oral and poster presentations at the 18th International Symposium on Amyloidosis (ISA) taking place September 4-8, 2022, in Heidelberg, Germany.

Key Points: 
  • These data were included in oral and poster presentations at the 18th International Symposium on Amyloidosis (ISA) taking place September 4-8, 2022, in Heidelberg, Germany.
  • Today the diagnosis of amyloidosis is a long, complex process, and many patients with systemic amyloidosis remain undiagnosed.
  • AT-01 is a pattern recognition peptide that binds electronegative motifs, fibrils, and highly sulfated heparan sulfate glycosaminoglycans in amyloid deposits.
  • Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis.